Hillebrands J L, Klatter F A, van den Hurk B M, Popa E R, Nieuwenhuis P, Rozing J
Department of Cell Biology, Immunology Section, University of Groningen, The Netherlands.
J Clin Invest. 2001 Jun;107(11):1411-22. doi: 10.1172/JCI10233.
The development of transplant arteriosclerosis (TA) is today's most important problem in clinical organ transplantation. Histologically, TA is characterized by perivascular inflammation and progressive intimal thickening. Current thought on this process of vascular remodeling assumes that neointimal vascular smooth muscle (VSM) cells and endothelium in TA are graft-derived, holding that medial VSM cells proliferate and migrate into the subendothelial space in response to signals from inflammatory cells and damaged graft endothelium. Using MHC class I haplotype-specific immunohistochemical staining and single-cell PCR analyses, we show that the neointimal alpha-actin-positive VSM cells in rat aortic or cardiac allografts are of recipient and not of donor origin. In aortic but not in cardiac allografts, recipient-derived endothelial cells (ECs) replaced donor endothelium. Cyclosporine treatment prevents neointima formation and preserves the vascular media in aortic allografts. Recipient-derived ECs do not replace graft endothelium after cyclosporine treatment. We propose that, although it progresses beyond the needs of functional repair, TA reflects the activity of a normal healing process that restores vascular wall function following allograft-induced immunological injury.
移植动脉硬化(TA)的发展是当今临床器官移植中最重要的问题。从组织学上看,TA的特征是血管周围炎症和内膜逐渐增厚。目前对于这种血管重塑过程的认识认为,TA中的新生内膜血管平滑肌(VSM)细胞和内皮细胞来源于移植物,即认为中膜VSM细胞会响应炎症细胞和受损移植物内皮细胞发出的信号而增殖并迁移至内皮下间隙。通过I类主要组织相容性复合体(MHC)单倍型特异性免疫组化染色和单细胞PCR分析,我们发现大鼠主动脉或心脏同种异体移植物中新生内膜α-肌动蛋白阳性VSM细胞来源于受体而非供体。在主动脉同种异体移植物中而非心脏同种异体移植物中,受体来源的内皮细胞(EC)取代了供体内皮。环孢素治疗可防止主动脉同种异体移植物中新生内膜形成并保留血管中膜。环孢素治疗后,受体来源的EC不会取代移植物内皮。我们提出,尽管TA的发展超出了功能修复的需求,但它反映了一种正常愈合过程的活动,该过程在同种异体移植诱导的免疫损伤后恢复血管壁功能。